Su X - Search Results

1

Vitamin C sensitizes BRAF^V600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032.

Su X, Li P, Han B, Jia H, Liang Q, Wang H, Gu M, Cai J, Li S, Zhou Y, Yi X, Wei W. Su X, et al. J Exp Clin Cancer Res. 2021 Jan 19;40(1):34. doi: 10.1186/s13046-021-01831-y. J Exp Clin Cancer Res. 2021. PMID: 33468157 Free PMC article.

2

Cordycepin inhibits the proliferation and progression of NPC by targeting the MAPK/ERK and β-catenin pathways.

Zhou Y, Mei X, Li Y, Yang W, Su X, Hu H. Zhou Y, et al. Among authors: su x. Oncol Lett. 2022 Jan;23(1):20. doi: 10.3892/ol.2021.13138. Epub 2021 Nov 16. Oncol Lett. 2022. PMID: 34858524 Free PMC article.

3

Human Organoids as a Promising Platform for Fighting COVID-19.

Chen D, Su X, Chen H, Chen S, Zhao Y, Wei W. Chen D, et al. Among authors: su x. Int J Biol Sci. 2022 Jan 1;18(3):901-910. doi: 10.7150/ijbs.64993. eCollection 2022. Int J Biol Sci. 2022. PMID: 35173525 Free PMC article. Review.

4

SGSM2 inhibits thyroid cancer progression by activating RAP1 and enhancing competitive RAS inhibition.

Su X, Chen D, Zhu L, Jia H, Cai J, Li P, Han B, Wang D, Li H, Fan J, Gu M, Zhou Y, Guan H, Wei W. Su X, et al. Cell Death Dis. 2022 Mar 9;13(3):218. doi: 10.1038/s41419-022-04598-y. Cell Death Dis. 2022. PMID: 35264562 Free PMC article.

5

Papillary thyroid cancer organoids harboring BRAF^V600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies.

Chen D, Su X, Zhu L, Jia H, Han B, Chen H, Liang Q, Hu C, Yang H, Liu L, Li P, Wei W, Zhao Y. Chen D, et al. Among authors: su x. J Transl Med. 2023 Jan 9;21(1):9. doi: 10.1186/s12967-022-03848-z. J Transl Med. 2023. PMID: 36624452 Free PMC article.

6

Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms.

Su X, Shen Z, Yang Q, Sui F, Pu J, Ma J, Ma S, Yao D, Ji M, Hou P. Su X, et al. Theranostics. 2019 Jun 9;9(15):4461-4473. doi: 10.7150/thno.35219. eCollection 2019. Theranostics. 2019. PMID: 31285773 Free PMC article.

7

CYP2S1 is a synthetic lethal target in BRAF^V600E-driven thyroid cancers.

Li Y, Su X, Feng C, Liu S, Guan H, Sun Y, He N, Ji M, Hou P. Li Y, et al. Among authors: su x. Signal Transduct Target Ther. 2020 Sep 11;5(1):191. doi: 10.1038/s41392-020-00231-6. Signal Transduct Target Ther. 2020. PMID: 32913191 Free PMC article.

8

The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53.

Su X, Feng C, Wang S, Shi L, Gu Q, Zhang H, Lan X, Zhao Y, Qiang W, Ji M, Hou P. Su X, et al. Cell Death Differ. 2021 Aug;28(8):2450-2464. doi: 10.1038/s41418-021-00762-7. Epub 2021 Mar 19. Cell Death Differ. 2021. PMID: 33742136 Free PMC article.

9

Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer.

Su X, Liu J, Zhang H, Gu Q, Zhou X, Ji M, Yao D. Su X, et al. Onco Targets Ther. 2020 Nov 2;13:11183-11192. doi: 10.2147/OTT.S278349. eCollection 2020. Onco Targets Ther. 2020. PMID: 33173310 Free PMC article.

10

Intermittent Use of Flash Glucose Monitoring Improves Glycemic Control in Chinese Older Patients with Type 2 Diabetes Mellitus.

Hu Y, Yan R, Shen Y, Li H, Ma J, Su X. Hu Y, et al. Among authors: su x. Diabetes Metab Syndr Obes. 2025 Jan 3;18:1-9. doi: 10.2147/DMSO.S498620. eCollection 2025. Diabetes Metab Syndr Obes. 2025. PMID: 39781244 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,604 results

Search Page

Filters